PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy
The programmed cell death 1 (PD-1) immune checkpoint of co-inhibitory signaling plays crucial roles in controlling the magnitude and duration of T cell activation to limit tissue damage and maintain self-tolerance. Cancer cells hijack the co-inhibitory pathway and escape immune surveillance by overe...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-04-01
|
| Series: | Cell Insight |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772892724000014 |
| _version_ | 1827572231563116544 |
|---|---|
| author | Rui Liu Hui-Fang Li Shu Li |
| author_facet | Rui Liu Hui-Fang Li Shu Li |
| author_sort | Rui Liu |
| collection | DOAJ |
| description | The programmed cell death 1 (PD-1) immune checkpoint of co-inhibitory signaling plays crucial roles in controlling the magnitude and duration of T cell activation to limit tissue damage and maintain self-tolerance. Cancer cells hijack the co-inhibitory pathway and escape immune surveillance by overexpressing the PD-1 ligand PD-L1. Immune checkpoint inhibitors, such as PD-1 blocking antibody have been approved for tumor immunotherapy. However, not all patients can benefit from PD-1 monotherapy. Combination immunotherapy based on PD-1 axis blockade substantially improves clinical anti-tumor efficacy. In this review, we briefly summarize the current progress on the mechanisms of PD-1-mediated inhibition of T cell activation and strategies for cancer combination immunotherapy. |
| first_indexed | 2024-03-07T22:00:41Z |
| format | Article |
| id | doaj.art-fdcb464a7bcf47da8f94c31d68417e76 |
| institution | Directory Open Access Journal |
| issn | 2772-8927 |
| language | English |
| last_indexed | 2024-04-24T16:25:17Z |
| publishDate | 2024-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cell Insight |
| spelling | doaj.art-fdcb464a7bcf47da8f94c31d68417e762024-03-31T04:38:14ZengElsevierCell Insight2772-89272024-04-0132100146PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapyRui Liu0Hui-Fang Li1Shu Li2Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China; Frontier Science Center for Immunology and Metabolism, Wuhan, 430071, China; Medical Research Institute, Wuhan, 430071, China; Research Unit of Innate Immune and Inflammatory Diseases (2019RU063), Chinese Academy of Medical Sciences, Wuhan, 430071, China; Wuhan University, Wuhan, 430071, ChinaDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China; Frontier Science Center for Immunology and Metabolism, Wuhan, 430071, China; Medical Research Institute, Wuhan, 430071, China; Research Unit of Innate Immune and Inflammatory Diseases (2019RU063), Chinese Academy of Medical Sciences, Wuhan, 430071, China; Wuhan University, Wuhan, 430071, ChinaDepartment of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China; Frontier Science Center for Immunology and Metabolism, Wuhan, 430071, China; Medical Research Institute, Wuhan, 430071, China; Research Unit of Innate Immune and Inflammatory Diseases (2019RU063), Chinese Academy of Medical Sciences, Wuhan, 430071, China; Wuhan University, Wuhan, 430071, China; Corresponding author. Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.The programmed cell death 1 (PD-1) immune checkpoint of co-inhibitory signaling plays crucial roles in controlling the magnitude and duration of T cell activation to limit tissue damage and maintain self-tolerance. Cancer cells hijack the co-inhibitory pathway and escape immune surveillance by overexpressing the PD-1 ligand PD-L1. Immune checkpoint inhibitors, such as PD-1 blocking antibody have been approved for tumor immunotherapy. However, not all patients can benefit from PD-1 monotherapy. Combination immunotherapy based on PD-1 axis blockade substantially improves clinical anti-tumor efficacy. In this review, we briefly summarize the current progress on the mechanisms of PD-1-mediated inhibition of T cell activation and strategies for cancer combination immunotherapy.http://www.sciencedirect.com/science/article/pii/S2772892724000014 |
| spellingShingle | Rui Liu Hui-Fang Li Shu Li PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy Cell Insight |
| title | PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy |
| title_full | PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy |
| title_fullStr | PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy |
| title_full_unstemmed | PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy |
| title_short | PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy |
| title_sort | pd 1 mediated inhibition of t cell activation mechanisms and strategies for cancer combination immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S2772892724000014 |
| work_keys_str_mv | AT ruiliu pd1mediatedinhibitionoftcellactivationmechanismsandstrategiesforcancercombinationimmunotherapy AT huifangli pd1mediatedinhibitionoftcellactivationmechanismsandstrategiesforcancercombinationimmunotherapy AT shuli pd1mediatedinhibitionoftcellactivationmechanismsandstrategiesforcancercombinationimmunotherapy |